## FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response:	S)														
Name and Address of Reporting Person * Dunne Michael W.					2. Issuer Name and Ticker or Trading Symbol Iterum Therapeutics plc [ITRM]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  X Director 10% Owner				
(Last) (First) (Middle) C/O ITERUM THERAPEUTICS PLC, FITZWILLIAM COURT, FL. 1, LEESON CLOSE					3. Date of Earliest Transaction (Month/Day/Year) 09/07/2022						Office	r (give title belo	ow)	Other (specify	pelow)	
(Street) DUBLIN 2, L2				4. If	4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person					
(City) (State) (Zip)					Table I - Non-Derivative Securities Acqui						ired, Disposed of, or Beneficially Owned					
1.Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year	2A. Deemed Execution Date, it any (Month/Day/Year		(Instr. 8)			(A) or Disposed of (Instr. 3, 4 and 5)		of (D)	D) Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		Collowing	Form: Direct (D) or Indirect (I)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Ordinary Shares		09/07/2022				ode P	V	10,000	\ /	Price \$ 2.22	35,576 <sup>(1)</sup>			D (Instr. 4)		
Terminaer.	report on a s	reparate fine is	or each class of secu Table II -	Deriv	rative Securit	ies A	equire	Perso conta the fo	ons wh ained in orm dis	no respor n this for splays a o	m are curre eficial	not requesting ntly valid	OMB conf	formation spond unle trol numbe	ss	1474 (9-02)
					puts, calls, w		ts, op									1
Security	2. Conversion or Exercise Price of Derivative Security	3. Transactio Date (Month/Day/	Execution D	ate, if	4. Transaction Code (Instr. 8)	5. Num of Deriv Secur Acqu (A) o Dispo of (D (Instr 4, and	vative rities cired or cosed c) : 3,	and Expiration Date (Month/Day/Year)  A US		Ame Und Sect	ount of erlying arities tr. 3 and Derivative Security (Instr. 5)		9. Number of Derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Owners Form of Derivat Security Direct ( or Indir	Beneficia Ownersh (Instr. 4)	
					Code V	(A)	(D)	Date Exer		Expiration Date	1 Title	Amount or Number of Shares				

### **Reporting Owners**

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Dunne Michael W. C/O ITERUM THERAPEUTICS PLC FITZWILLIAM COURT, FL. 1, LEESON CLOSE DUBLIN 2, L2	X					

### **Signatures**

/s/ Michael W. Dunne	09/09/2022
**Signature of Reporting Person	Date

#### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) On August 17, 2022 the Issuer effected a 1 for 15 reverse share split (the "Reverse Share Split"). The number of ordinary shares reported on this Form 4 have been adjusted to reflect the Reverse Share Split.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.